Literature DB >> 12113989

Simultaneous determination of indinavir, ritonavir and lopinavir (ABT 378) in human plasma by high-performance liquid chromatography.

John Ray1, Edna Pang, Dianne Carey.   

Abstract

An isocratic reversed-phase high-performance liquid chromatographic method with ultraviolet detection at 205 nm has been validated for the determination of indinavir, ritonavir and lopinavir (ABT 378) in human plasma. The ritonavir analogue A-86093.0 was used as internal standard. Good chromatographic separation was achieved using a stainless steel column packed with 5 microm Phenomenex phenyl hexyl material operated at 40 degrees C, and a mobile phase consisting of acetonitrile-10 mM potassium phosphate buffer (50:50, v/v). The calibration curve for indinavir was linear over the range of 50 to 1000 microg/l while the ritonavir and lopinavir calibration curves were linear over the range of 100 to 15,000 microg/l. The lower limit of quantitations for indinavir, ritonavir and lopinavir were 50, 100 and 100 microg/l, respectively, using 500 microl of human plasma. The validation data showed that the assay is sensitive, specific and reproducible for determination of indinavir, ritonavir and lopinavir. This method is being used in a therapeutic drug monitoring service to quantitate these therapeutic agents in patients infected with human immunodeficiency virus. Copyright 2002 Elsevier Science BV.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12113989     DOI: 10.1016/s1570-0232(02)00295-7

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  2 in total

1.  Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malaria.

Authors:  Katherine T Andrews; David P Fairlie; Praveen K Madala; John Ray; David M Wyatt; Petrina M Hilton; Lewis A Melville; Lynette Beattie; Donald L Gardiner; Robert C Reid; Martin J Stoermer; Tina Skinner-Adams; Colin Berry; James S McCarthy
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

2.  Therapeutic drug monitoring of atazanavir: surveillance of pharmacotherapy in the clinic.

Authors:  John E Ray; Debbie Marriott; Mark T Bloch; Andrew J McLachlan
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.